Scholar Rock Holding Corp SRK-015 Interim Phase 1 Results and Phase 2 Trial Design Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the Scholar Rock SRK-015 Interim Phase 1 results and Phase 2 overview. (Operator Instructions)
I would now like to hand the call over to Ms. Catherine Hu, Investor Relations. You may begin.
Thanks, Amanda. Good morning, and thank you for joining us on today's call to discuss the interim results from the Phase 1 trial of SRK-015 in healthy volunteers and an overview of the Phase 2 trial in SMA.
Today's call will be led by Nagesh Mahanthappa, our President, CEO; and Yung Chyung, our Chief Medical Officer. Nagesh and Yung will be joined by Alan Buckler, our Chief Scientific Officer; and Rhonda Chicko, our Chief Financial Officer for Q&A.
The webcast slides can be downloaded on the Events & Presentations section of the Investor Relations page on the Scholar Rock website.
Before I turn it over to Nagesh, I wanted you to know that we'll be making various
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |